Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Failure To Renegotiate With Ranbaxy Puzzles Analysts

This article was originally published in PharmAsia News

Executive Summary

Pharmaceutical industry analysts wonder why Daiichi Sankyo failed to renegotiate its $4.2 billion purchase of Ranbaxy Laboratories when the Indian generics maker encountered problems. The same analysts saw the merger as a good marriage of a branded company with a generic to give Daiichi a stronger presence in other markets. But after the U.S. FDA banned 30 Ranbaxy products in September, the Indian company lost 10 percent of its global sales and half of its U.S. sales, with a concomitant fall in stock value. The analysts believe Daiichi had an opportunity to renegotiate its offer in the intervening two months before the sale was completed. (Click here for more - a subscription may be required

You may also be interested in...

Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts